Navigation Links
Parkinson's Disease Medication Triggers Destructive Behaviors
Date:4/8/2009

/p>

The researchers analyzed the medical records of patients with Parkinson's disease residing in counties surrounding Rochester, Minn., who received their primary neurological care at Mayo Clinic in Rochester between 2004 and 2006. This group included 267 patients. Of those, 66 were taking dopamine agonists for their Parkinson's disease. Of those 66, 38 were taking the drugs in therapeutic doses (doses expected to be at least minimally beneficial).

The findings were definitive. Seven patients experiencing new-onset compulsive gambling or hypersexuality were taking dopamine agonists in therapeutic doses. None of the other Parkinson's disease patients developed compulsive gambling habits or hypersexuality, including the 28 patients on subtherapeutic dopamine agonist doses or the other 201 patients not taking dopamine agonists. None of the 178 patients treated only with the standard drug for Parkinson's disease, carbidopa/levodopa, developed these behaviors.

"It is crucial for clinicians prescribing dopamine agonists to apprise patients as well as their spouses or partners about this potential side effect. The onset can be insidious and overlooked until life-altering problems develop," says J. Eric Ahlskog, M.D., Ph.D., Mayo Clinic neurologist who co-authored and treated many of the patients in the 2005 study. "It also is worth noting that the affected patients were all taking therapeutic doses. Very low doses, such as those used to treat restless legs syndrome, carry much less risk."

"For some patients, a reduction in the dose of the dopamine agonist may prove to be sufficient treatment," says Dr. Ahlskog, "although total elimination of the offending drug is often necessary."

A peer-review journal, Mayo Clinic Proceedings publishes original articles and reviews dealing with clinical and laboratory medicine, cl
'/>"/>

SOURCE Mayo Clinic
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Michael J. Fox Foundation Commits up to $6.5 Million in Funding for Critical Challenges in Parkinsons Disease
2. SYNTAX Analysis Finds Treatment With TAXUS(R) Express2(TM) Stents More Cost Effective Than Bypass Surgery in Many Patients With Complex Coronary Artery Disease
3. Michael J. Fox Foundation Awards $2.1 Million to Improve Drug Delivery in Parkinsons Disease
4. Medgenics Phase I/II Clinical Trial Now Shows EPODURE Continuous Anemia Treatment Lasting 5 Months in Kidney Disease Patients
5. Following Encouraging Results Anthera to Continue IMPACTS Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
6. Task Force Recommends Using Aspirin to Prevent Cardiovascular Disease When the Benefits Outweigh the Harms
7. Metastatic Bone Disease Patients Can Walk in Lazarus Footsteps
8. Tevas Azilect Use Dramatically Increases in Second-Line Therapy for the Treatment of Parkinsons Disease
9. Amicus Therapeutics Suspends Enrollment for Phase 2 Clinical Trial of AT2220 for Pompe Disease
10. The Childrens Hospital of Philadelphia: New Gene-Searching Method Uncovers Possible New Targets for Crohns Disease Drugs
11. Report on 300 New Medicines in Development for Heart Disease and Stroke Released in Indianapolis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... -- ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV ), a ... targeted antiviral therapies, announced today that it will present ... in New York, NY on ... James Sapirstein , Chief Executive Officer, ... his live presentation and will be available to participate ...
(Date:7/1/2015)... DUBLIN , June 24, 2015 /PRNewswire/ ... http://www.researchandmarkets.com/research/34xqr7/2015_new ) has announced the addition of ... Clinical Chemistry and Immunodiagnostic Markets: Business Challenges, ... their offering. 2015 New Frontiers ... Business Challenges, Emerging Technologies, Competitive Landscape is ...
(Date:7/1/2015)... , July 1, 2015 According ... Adhesives Market by Product (Natural & Synthetic, Fibrin, Collagen, ... Cosmetic Surgery) - Global Forecast to 2020", published by ... estimated to reach $2.64 Billion by 2020, growing at ... to 2020). Browse 119 market T ...
Breaking Medicine Technology:ContraVir to Present at Cantor Fitzgerald Inaugural Healthcare Conference 22015 New Frontiers in European Clinical Chemistry and Immunodiagnostic Markets: Business Challenges, Emerging Technologies, Competitive Landscape 2Surgical Sealants and Adhesives Market Worth $2.64 Billion by 2020 2Surgical Sealants and Adhesives Market Worth $2.64 Billion by 2020 3Surgical Sealants and Adhesives Market Worth $2.64 Billion by 2020 4
... April 27 SI-BONE, Inc. ( Cupertino, California ), ... minimally invasive surgical (MIS) device to treat the sacroiliac (SI) joint ... at upcoming 2010 minimally invasive spine surgery meetings. , ... SI-BONE has been working with ...
... CareFusion Corporation (NYSE: CFN ) today announced plans to release third ... close of trading on the New York Stock Exchange. , ... The company will host a webcast and conference call on May 6 ... to discuss the results for its third quarter, ended on March 31, 2010 ...
Cached Medicine Technology:iFuse Implant System(TM) to be Presented at Leading Minimally Invasive Spine Surgical Meetings 2iFuse Implant System(TM) to be Presented at Leading Minimally Invasive Spine Surgical Meetings 3iFuse Implant System(TM) to be Presented at Leading Minimally Invasive Spine Surgical Meetings 4CareFusion Will Host an Earnings Conference Call on May 6 to Discuss the Results for the Third Quarter of Fiscal 2010 2
(Date:7/2/2015)... ... July 02, 2015 , ... Scientists at ... nearly $4 million through five federal grants to study a group of related ... deadly diseases. , The research will be conducted in the Regional Biocontainment ...
(Date:7/2/2015)... ... July 02, 2015 , ... ... healthcare providers, has been retained to lead a national chief operating officer ... executive search firms in the healthcare industry, B. E. Smith has recently placed ...
(Date:7/2/2015)... ... July 02, 2015 , ... Evolved Ayurvedic Discoveries , ... an intention to partner with companies that share a similar mission of providing ... water soluble, Cannabidiol (CBD) formulations, combined with Ayurvedic herbs, are now available for ...
(Date:7/2/2015)... ... ... A team of quality control (QC) experts at GE Healthcare, led by ... enhanced workflow. Now, Dr. Dunne’s lab has set a lofty goal: to become the ... network. , Join the team members for a new, free educational webinar ...
(Date:7/2/2015)... ... July 02, 2015 , ... Cs &A, the ... Timing announced the release and publication of their newest offering to complement the ... and Newsletter. , Designed in support of coverage for the full spectrum ...
Breaking Medicine News(10 mins):Health News:Mosquito-Borne Viruses Subject of $4M in Federal Grants to Scientists in Pitt’s Center for Vaccine Research 2Health News:Mosquito-Borne Viruses Subject of $4M in Federal Grants to Scientists in Pitt’s Center for Vaccine Research 3Health News:Mosquito-Borne Viruses Subject of $4M in Federal Grants to Scientists in Pitt’s Center for Vaccine Research 4Health News:Nicklaus Children’s Hospital Retains B. E. Smith to Recruit New Chief Operating Officer 2Health News:Nicklaus Children’s Hospital Retains B. E. Smith to Recruit New Chief Operating Officer 3Health News:New Water Soluble CBD Provides Manufacturers & Distributors a More Effective, Safe, & Cost Efficient Alternative to Traditional CBD Oil 2Health News:New Water Soluble CBD Provides Manufacturers & Distributors a More Effective, Safe, & Cost Efficient Alternative to Traditional CBD Oil 3Health News:GE Healthcare Webinar Spotlights GE’s Own, Internal QC Lab Enhancements with Six Sigma 2Health News:GE Healthcare Webinar Spotlights GE’s Own, Internal QC Lab Enhancements with Six Sigma 3Health News:Cs &A Releases the SEMI TIMING Newsletter Specific to the Semiconductor Timing Industry 2Health News:Cs &A Releases the SEMI TIMING Newsletter Specific to the Semiconductor Timing Industry 3Health News:Cs &A Releases the SEMI TIMING Newsletter Specific to the Semiconductor Timing Industry 4
... in blood pressure, disease scores , , SUNDAY, March 30 ... electronically, good doctor-patient communication helps reduce the risk of ... study. , The four-year study included rural and urban ... were otherwise healthy. They were divided into two groups, ...
... agent that combines 2 medications , , SUNDAY, March 30 (HealthDay ... to make sense of a trial showing that a drug ... no apparent benefit to people at high risk of heart ... a well-known statin -- simvastatin -- with ezetimibe, which also ...
... In a comparison of anticoagulants and stents for use ... and tirofiban had similar outcomes for some cardiac measures ... received stents that released the drug sirolimus had a ... months than patients who received uncoated stents, according to ...
... restenosis risk and don,t increase mortality probability , , SUNDAY, ... tubing placed in diseased coronary arteries to keep them ... attack patients, new research shows. , In the largest ... -- the drug in question retards the growth of ...
... RN ... Organization, HOUSTON, March 29 ... a stronger voice to speak,out for patients and themselves, a northwest Houston ... bargaining,rights., RNs at Cypress Fairbanks Medical Center Hospital voted 119 to ...
... cancer deaths could be avoided with lifestyle changes, experts ... therapies that could cut cancer deaths in half. , ... recent American Cancer Society report that said as many ... with lifestyle changes, such as quitting smoking, maintaining a ...
Cached Medicine News:Health News:Combining Internet With Office Visits Cut Heart Attack Risks 2Health News:Cholesterol Drug Controversy Continues 2Health News:Cholesterol Drug Controversy Continues 3Health News:Comparison of anticoagulants for angioplasty show similar outcomes 2Health News:Drug-Eluting Stents Safe After Heart Attack 2Health News:First Unionized Hospital in Texas 2Health News:First Unionized Hospital in Texas 3Health News:You May Be the Key to Cancer Prevention 2Health News:You May Be the Key to Cancer Prevention 3
... AT20R places fast and accurate ... fingertips. Utilising standard computer hardware ... environment with new testing and ... easily integrated into a modern ...
... a test capability extending to 80, the ... patient's visual field, allowing peripheral defects that ... to be explored. Practice Management Integration provides ... With the Medmont Studio package the practitioner ...
... SNPstream Genotyping System provides an automated scalable ... over 800,000 SNP genotypes per day. Combined ... flexibility, this enables you to process a ... robust solution designed to deliver your intended ...
Egg-Shaped Bioceramic orbital implants insert easily into orbital socket and will not cling to surrounding tissue. Improved interconnectivity between pores enhances vascularization. Implants may be e...
Medicine Products: